Pharmacokinetics and pharmacodynamics of vincristine sulfate liposome injection (VSLI) in adults with acute lymphoblastic leukemia.
作者： Jeffrey A. Silverman , Laurie Reynolds , Steven R. Deitcher
DOI: 10.1002/JCPH.155
关键词:
摘要: Vincristine sulfate liposome injection (VSLI,) is a sphingomyelin and cholesterol nanoparticle formulation of vincristine (VCR) that was designed to overcome the dosing pharmacokinetic limitations standard VCR. In contrast rapid CL wide tissue distribution non-liposomal VCR, VSLI circulates in plasma for prolonged period time, with slow 345 mL/h relatively small Vd 3,570 mL. This facilitates enhanced tumor-tissue delivery The maximum tolerated dose VSLI, 2.25 mg/m(2) once per week without cap, enables individual cumulative VCR exposure unachievable at its labeled 1.4 mg/m(2) . associated dose-dependent peripheral neurotoxicity albeit doses are two three times intensification correlated an increased probability overall response strong trend towards complete adults relapsed and/or refractory acute lymphoblastic leukemia. Overall, improves therapeutic index by facilitating while maintaining predictable manageable safety profile.
sci-hub.se 参考文章(35)
A. Bult, J. H. M. Sips, J. H. Beijnen, O. Van Tellingen, W. J. Nooijen, Pharmacology, bio-analysis and pharmacokinetics of the vinca alkaloids and semi-synthetic derivatives (review). Anticancer Research. ,vol. 12, pp. 1699- 1715 ,(1992)
Frederick O. Hains, Richard J. Owellen, Mary A. Root, Pharmacokinetics of Vindesine and Vincristine in Humans Cancer Research. ,vol. 37, pp. 2603- 2607 ,(1977)
Dan L. Longo, Vincent T. DeVita, Susan Molloy Hubbard, The chemotherapy of lymphomas: looking back, moving forward--the Richard and Hinda Rosenthal Foundation award lecture. Cancer Research. ,vol. 47, pp. 5810- 5824 ,(1987)
M. A. Rodriguez, Robert Pytlik, Tomas Kozak, Mukesh Chhanabhai, Randy Gascoyne, Biao Lu, Steven R. Deitcher, Jane N. Winter, , Vincristine sulfate liposomes injection (Marqibo) in heavily pretreated patients with refractory aggressive non-Hodgkin lymphoma: report of the pivotal phase 2 study. Cancer. ,vol. 115, pp. 3475- 3482 ,(2009) , 10.1002/CNCR.24359
W.G. Bradley, L.P. Lassman, G.W. Pearce, J.N. Walton, The neuromyopathy of vincristine in man Journal of the Neurological Sciences. ,vol. 10, pp. 107- 131 ,(1970) , 10.1016/0022-510X(70)90013-4
Frederick Richards, V. Sagar Sethi, M. Robert Cooper, Charles L. Spurr, Douglas R. White, Don V. Jackson, Hyman B. Muss, John J. Stuart, Pharmacokinetics of Vincristine Sulfate in Adult Cancer Patients Cancer Research. ,vol. 41, pp. 3551- 3555 ,(1981)
D L Longo, R C Young, M Wesley, S M Hubbard, P L Duffey, E S Jaffe, V T DeVita, Twenty years of MOPP therapy for Hodgkin's disease. Journal of Clinical Oncology. ,vol. 4, pp. 1295- 1306 ,(1986) , 10.1200/JCO.1986.4.9.1295
Edward K. Russell, Bruce E. Johnson, Adi F. Gazdar, Mark S. Georgiadis, Paclitaxel cytotoxicity against human lung cancer cell lines increases with prolonged exposure durations. Clinical Cancer Research. ,vol. 3, pp. 449- 454 ,(1997)
H. W. Van den Berg, Z. R. Desai, R. Wilson, G. Kennedy, J. M. Bridges, R. G. Shanks, The pharmacokinetics of vincristine in man: reduced drug clearance associated with raised serum alkaline phosphatase and dose-limited elimination. Cancer Chemotherapy and Pharmacology. ,vol. 8, pp. 215- 219 ,(1982) , 10.1007/BF00255487
E. B. CASEY, A. M. JELLIFE, PAMELA M. LE QUESNE, YVONNE L. MILLETT, Vincristine neuropathy. Clinical and electrophysiological observations. Brain. ,vol. 96, pp. 69- 86 ,(1973) , 10.1093/BRAIN/96.1.69